medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Número 3

<< Anterior Siguiente >>

Ann Hepatol 2016; 15 (3)


Nonalcoholic steatohepatitis in morbid obese patients: coffee consumption vs. disease severity

Barros RK, Cotrim HP, Daltro C, Alves E, de Freitas LAR, Daltro C, Oliveira Y

Idioma: Ingles.
Referencias bibliográficas: 34
Paginas: 350-355
Archivo PDF: 182.39 Kb.


RESUMEN

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol 2012; 56: 704-13.

  2. Karlas T, Wiegand J, Berg T. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab 2013; 27: 195-208.

  3. Cerovic I, Mladenovic D, Ješic R, Naumovic T, Brankovic M, Vucevic D, Aleksic V, et al. Alcoholic liver disease/nonalcoholic fatty liver disease index: distinguishing alcoholic from nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2013; 25: 899-904.

  4. Puppala J, Siddapuram SP, Akka J, Munshi A. Genetics of nonalcoholic fatty liver disease: an overview. J Genet Genomics 2013; 40: 15-22.

  5. Diehl AM. Hepatic complications of obesity. Gastroenterol Clin N Am 2010; 39: 57-68.

  6. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-8.

  7. Serviddio G, Bellanti F, Vendemiale G. Free radical biology for medicine: learning from nonalcoholic fatty liver disease. Free Radic Biol Med 2013; 65: 952-68.

  8. Lee M, Kowdley KV. Alcohol’s effect on other chronic liver diseases. Clin Liver Dis 2012; 16: 827-37.

  9. Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ, Nonalcoholic Steatohepatitis Clinical Research Network. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol 2011; 54: 753-9.

  10. Dunn W, Sanyal AJ, Brunt EM, Unalp-Arida A, Donohue M, McCullough AJ, Schwimmer JB. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2012; 57: 384-91.

  11. Rodriguez B, Torres DM, Harrison SA. Physical activity: an essential component of lifestyle modification in NAFLD. Nat Rev Gastroenterol Hepatol 2012; 9: 726-31.

  12. Vos MB, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology 2013; 57: 2525-31.

  13. Chen S, Teoh NC, Chitturi S, Farrell GC. Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection? J Gastroenterol Hepatol 2014; 29: 435-41.

  14. Yesil A, Yilmaz Y. Review article: coffee consumption, the metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013; 38: 1038-44.

  15. Butt MS, Sultan MT. Coffee and its consumption: benefits and risks. Crit Rev Food Sci Nutr 2011; 51: 363-73.

  16. Cadden IS, Partovi N, Yoshida EM. Review article: possible beneficial effects of coffee on liver disease and function. Aliment Pharmacol Ther 2007; 26: 1-8.

  17. Saab S, Mallam D, Cox II GA, Tong MJ. Impact of coffee on liver diseases: a systematic review. Liver Int 2014; 34: 495-504.

  18. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012; 55: 429-36.

  19. Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander- Tetri BA, Brunt EM, Bass NM, et al. Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int 2014; 34: 1250-8.

  20. Matthews DR. Insulin resistance and β-cell function – a clinical perspective. Diabetes Obes Metab 2001; 3: 28-33.

  21. Kuwana B, Urayama O, Kawai K. Reference value and cutoff value for diagnosis of insulin resistance in type 2 diabetes mellitus. Rinsho Byori [Jpn J Clin Pathol] 2002; 50: 398-403.

  22. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97.

  23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.

  24. Santos CE, Schrank Y, Kupfer R. Análise crítica dos critérios da OMS, IDF e NCEP para síndrome metabólica em pacientes portadores de diabetes melito tipo 1 [Critical analysis of WHO, IDF and NCEP criteria for metabolic syndrome in patients with type 1 diabetes mellitus]. Arq Bras Endocrinol Metab 2009; 53: 1096-102.

  25. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-20.

  26. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009; 50: 1360-9.

  27. Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 35: 76-82.

  28. Anty R, Marjoux S, Iannelli A, Patouraux S, Schneck AS, Bonnafous S, Gire C, et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol 2012; 57: 1090-6.

  29. Catalano D, Martines GF, Tonzuso A, Pirri C, Trovato FM, Trovato GM. Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2010; 55: 3200-6.

  30. Gutiérrez-Grobe Y, Chávez-Tapia N, Sánchez-Valle V, Gavilanes-Espinar JG, Ponciano-Rodríguez G, Uribe M, Méndez-Sánchez N. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. Ann Hepatol 2012; 11: 350-5.

  31. de Moura Almeida A, Cotrim HP, Barbosa DB, de Athayde LG, Santos AS, Bitencourt AG, de Freitas LA, et al. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. World J Gastroenterol 2008; 14: 1415-8.

  32. Modi AA, Feld JJ, Park Y, Kleiner DE, Everhart JE, Liang TJ, Hoofnagle JH. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010; 51: 201-9.

  33. van Dam RM. Coffee consumption and risk of type 2 diabetes, cardiovascular diseases, and cancer. Appl Physiol Nutr Metab 2008; 33: 1269-83.

  34. van Dam RM, Hu FB. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA 2005; 294: 97-104.




2020     |     www.medigraphic.com